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CommentaryAlthough the HIV/AIDS Reporting System (eHARS) 
is the cornerstone of surveillance of HIV disease, sup-
plemental surveillance projects have provided addi-
tional information about care seeking, health care 
utilization, and behaviors. In 2005, in response to an 
Institute of Medicine Report [1], the Centers for Dis-
ease Control and Prevention (CDC) implemented the 
Medical Monitoring Project (MMP), a nationally rep-
resentative, population-based surveillance system to 
assess clinical and behavioral outcomes among HIV-
infected persons [2]. In future cycles, MMP data will 
be used to provide nationally representative estimates 
of clinical and behavioral indicators among HIV-
infected persons receiving care in the United States 
and to describe HIV comorbidities, disease manage-
ment, and quality of care. The data will also be used to 
identify gaps in services and allocate local HIV/AIDS 
services and resources for this population.
This surveillance report focuses on interview data 
from the pilot MMP cycle, during which information 
was collected on patients in care during 2005. Data 
were collected during January 2006–August 2007. 
Interviews were conducted in 10 project areas: 
Delaware, Houston (Texas), Los Angeles County 
(California), Maryland, Michigan, New Jersey, 
Philadelphia (Pennsylvania), South Carolina, Texas, 
and Washington. (See Technical Notes for more infor-
mation on MMP methods.)
Of the 899 persons who participated in MMP, 72% 
were male, 26% were female, and 2% were transgen-
der. Participants were of diverse racial and ethnic 
backgrounds and age groups. Most participants were 
black (47%) or white (30%). Most participants were 
aged 35–44 (38%) or 45–54 (37%); 40% had more 
than a high school education. Most participants (87%) 
were born in the United States. For most participants 
(65%), HIV infection had been diagnosed more than 5 
years earlier. Of the 768 participants who reported 
having any type of health insurance during the past 12 
months, most reported having Medicaid (47%) or 
Medicare (41%) (Table 1).
The benefits of treatment given early in the course 
of HIV infection are increased survival, reduced mor-
bidity, improved quality of life, lower medical care 
costs, and reduced transmission [3, 4]. MMP respon-HIV Special Surveillance Report 6dents cited structural, financial, and personal or cul-
tural barriers to entering care. A total of 132 persons 
reported that they had delayed HIV care for 4 months 
and selected 1–3 reasons for the delay (Table 2). The 
reason mentioned by the largest percentage of respon-
dents (37%) was “didn’t want to think about being 
HIV-positive.” Given the reasons provided in this 
report for not seeking HIV care within 4 months after 
diagnosis, efforts are needed to reduce barriers to 
obtaining care.
The following list reflects the services needed (dur-
ing the past 12 months) by the largest proportions of 
892 MMP respondents: HIV case management (46%), 
mental health counseling (30%), social services (30%; 
e.g., insurance assistance or financial counseling), and 
assistance with finding dental services (28%). The 
need remained unmet for 36 (9%) of those needing 
HIV case management, 31 (12%) of those needing 
mental health counseling, 31 (12%) of those needing 
social services, and 51 (20%) of those needing assis-
tance with finding dental services (Table 3).
Monitoring CD4 T-lymphocyte cell counts and viral 
load test results are an integral part of HIV disease 
management. For patients who are taking antiretrovi-
ral (ARV) medication, the results of HIV viral load 
tests are the most important indicator of patients’ 
response to treatment [5]. In general, CD4 cell counts 
and viral load should be monitored every 3–4 months 
according to current guidelines [5]. CD4 cell counts 
and the results of viral load tests are often used as clin-
ical markers to determine whether HIV-infected per-
sons are receiving health care [6]. Of 690 participants 
who had undergone a CD4 test during the past 12 
months and knew their most recent CD4 count, 115 
(17%) reported a CD4 count of <200 cells/mm3, and 
249 (36%) reported a CD4 count of 500 cells/mm3 
(Figure 1). Of 834 participants who had at least one 
CD4 test during the past 12 months, 559 (67%) 
reported that they had been tested 3–4 times (Figure 2).
Of 646 participants who had undergone an HIV viral 
load test during the past 12 months and who knew their 
most recent viral load, 384 (59%) reported that the level 
had been below the level of detection (undetectable) 
(Figure 3). Of 818 participants who had at least one 5
viral load test during the past 12 months, 540 (66%) 
reported that they had been tested 3–4 times (Figure 4). 
Of 890 participants, 827 (93%) reported ever having 
taken ARV medication for HIV infection; 63 (7%) 
reported never having taken ARV medication. Among 
the participants who had never taken ARV medication, 
the most common reasons reported for not doing so 
were that their CD4 cell count or viral load or both 
were good (54%), that they followed a doctor’s advice 
to delay treatment (38%), and that they felt good and 
didn’t need them (14%). A total of 80 participants who 
were not currently taking ARV medications reported 
the following as their most common reasons: followed 
doctor’s advice to delay treatment (31%), worried 
about side effects (23%), and CD4 cell count or viral 
load was good (20%) (Table 4).
Adherence to ARV medication is associated with 
improved clinical outcomes [5]. Self-reported measures 
of adherence are associated with HIV viral load [7]. In 
this report, 717 participants reported currently taking 
any ARV medications. Of these, 241 (34%) participants 
had not been fully adherent to their ARV dosing sched-
ule during the month before interview and 239 gave a 
reason for missing their most recent dose. Among the 
participants who gave a reason, the most common rea-
sons given were forgetting (37%) and a change in daily 
routine (17%) (Table 5).
Data on alcohol and drug use during the past 12 
months indicate that a total of 468 (52%) participants 
reported using alcohol or noninjection drugs (i.e., 
drugs not used for medical purposes). Excluding 
alcohol, a total of 277 participants reported use of non-
injection drugs (Table 6). Of these, 200 (72%) reported 
using marijuana. The other most frequently reported 
noninjection drugs were cocaine (smoked or snorted, 
24%), crack (24%), and methamphetamines (17%). A 
total of 31 participants reported having injected drugs 
(i.e., drugs not used for medical purposes) during the 
past 12 months. The drugs most frequently reported 
were methamphetamines (61%), heroin (39%), 
cocaine (32%), and heroin and cocaine together (32%) 
(Table 7).
Data on sexual behavior during the past 12 months 
indicate that risky sexual behaviors were common. Of 
234 male participants who reported having anal sex 
with at least one man, 118 (50%) reported having 
unprotected anal sex (Figure 5). Of 130 male partici-
pants who reported having anal or vaginal sex with at 
least one woman, 49 (38%) reported having unpro-HIV Special Surveillance Report 6tected anal or vaginal sex (Figure 5). A total of 189 
(82%) men who have sex with men reported knowing 
the HIV status of their most recent male sex partner, 
and a total of 97 (77%) men who have sex with women 
reported knowing the HIV status of their most recent 
female partner (Figure 6).
Of 132 female participants who reported having had 
anal or vaginal sex with at least one man during the 
past 12 months, 62 (47%) reported having unprotected 
anal or vaginal sex (Figure 5). A total of 110 (87%) 
knew the HIV status of their most recent male partner 
(Figure 6).
A total of 574 (64%) participants in 9 project areas 
(see Technical Notes) were asked questions about HIV 
prevention. During the past 12 months, excluding HIV 
pretest and posttest counseling, 101 (18%) participants 
had a one-on-one conversation with an outreach 
worker, counselor, or prevention program worker 
about ways to protect themselves or their partners from 
HIV infection or other sexually transmitted diseases. 
Of these 101 participants, 83 (82%) discussed ways to 
talk with a partner about safer sex, and 83 (82%) dis-
cussed ways to use condoms effectively. 
During the past 12 months, excluding discussions 
with friends, 62 (11%) had participated in at least one 
small-group session to discuss ways to prevent HIV 
infection. Of these 62 participants, 49 (79%) had dis-
cussed ways to talk with a partner about safer sex, and 
48 (77%) discussed ways to effectively use condoms.
A total of 303 (53%) participants had received free 
condoms from various organizations during the past 
12 months. Of these participants, 96 (32%) had 
received condoms from HIV/AIDS-focused commu-
nity-based organizations, 108 (36%) from a commu-
nity public health clinic, and 57 (18%) from an adult 
HIV/AIDS specialty clinic. Most participants (62%) 
stated that they had used the free condoms they 
received, and 167 (55%) stated that receiving these 
free condoms made them more likely to use condoms 
during sex. 
To achieve several of the goals of CDC’s HIV Pre-
vention Strategic Plan through 2010 [8], information is 
needed about the prevalence of behavioral and clinical 
outcomes among HIV-infected persons. State and 
local jurisdictions can use MMP data to guide HIV 
prevention planning and allocate resources to maxi-
mize efficiencies in care and treatment [8].6
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Technical NotesThis report presents interview data collected during 
the 2005 pilot cycle of the MMP. Data were collected 
from January 2006 through August 2007. A total of 13 
project areas were funded to conduct data collection 
activities for this pilot cycle. Interviews were conduct-
ed in 10 of the 13 project areas: Delaware, Houston 
(Texas), Los Angeles County (California), Maryland, 
Michigan, New Jersey, Philadelphia (Pennsylvania), 
South Carolina, Texas, and Washington. Medical 
record abstractions were conducted in 6 project areas: 
Houston (Texas), Los Angeles County (California), 
Michigan, New York City (New York), Texas, and 
Washington. Data from the medical record abstraction 
component of MMP are not presented in this report.
The following are the eligibility criteria for patients 
in all participating project areas: diagnosis of HIV 
infection, age of 18 years, not a previous participant in 
the current MMP cycle, recipient of medical care during 
a defined 3-month period, and able to provide informed 
consent. Sampled participants who died before inter-
view were considered ineligible. Eligible facilities were 
medical practices in which clinicians ordered tests of 
CD4 cell counts or HIV viral load or who prescribed 
ARV medications to HIV-infected patients. 
In each MMP data collection cycle, behavioral infor-
mation is collected by using a standardized question-
naire. The questionnaire is administered during a 
face-to-face interview, conducted by a trained inter-
viewer who records information on a laptop, a handheld 
computer, or a paper form. The laptop and handheld 
devices are equipped with encryption software. CDC’s 
Institutional Review Board determined that MMP was 
public health surveillance, not a research activity; how-
ever, all state and local jurisdictions were responsible 
for requesting review for the protection of human sub-
jects in their respective project areas.
MMP SAMPLING METHOD
A 3-stage sampling design was used to obtain cross-
sectional probability samples of HIV-infected adults 
receiving care in the United States. The MMP sample 
is selected in the following 3 stages. 
Selection of states. States were selected as the first 
of the 3 sampling stages. All 50 states, the District of 
HIV Special Surveillance Report 6Columbia, and Puerto Rico (defined as primary sam-
pling units) were eligible for selection. During this 
first stage of sampling, 20 geographic primary sam-
pling units were selected by using probability-
proportional-to-size sampling based upon AIDS 
prevalence at the end of 2002. Thus, the probability of 
selection was higher for states with higher AIDS prev-
alence and lower for states with lower prevalence. If a 
state included a city with an independent HIV/AIDS 
surveillance authority (e.g., Texas includes indepen-
dently funded Houston), selection of the state included 
selection of the city (i.e., city-state pairs were selected 
as one unit). 
Facilities providing HIV care. Selection of HIV 
care facilities was the second of the 3 sampling stages. 
In each participating jurisdiction, comprehensive lists 
of facilities providing HIV care were compiled by 
MMP staff. A measure of size (estimated patient load 
during a defined 3-month period) for each facility was 
determined on the basis of direct contact with the facil-
ity or from other sources. From these lists, HIV care 
facilities were sampled according to the likelihood of 
selection proportional to their estimated patient load. 
The probability of selection was higher for facilities 
with higher estimated patient loads and lower for facil-
ities with lower estimated patient loads. Facilities that 
did not provide medical care, such as HIV counseling 
and testing sites, were excluded from the list of facili-
ties. Other facilities that were excluded were emer-
gency departments, facilities located outside the MMP 
project area’s jurisdiction, federal prisons, health care 
facilities located on military installations, and facilities 
that provide HIV care exclusively to persons aged <18 
years. Because the 2005 MMP activities were pilot 
activities, time constraints dictated that not all sample-
selected facilities were recruited for participation.
Patients receiving care. Selection of individual 
patients was the third and final sampling stage. Each 
participating facility compiled comprehensive lists of 
eligible patients seen during a defined 3-month period, 
called the population definition period. Each project 
area determined its own population definition period 
depending upon when pilot activities began. The sam-
ple of patients was selected from the compilation of 
the lists of eligible patients in each jurisdiction. 8 
Because the 2005 MMP activities were pilot activities, 
time constraints dictated that not all sample-selected 
patients were recruited.
PARTICIPANT RECRUITMENT
Persons selected in the third stage of sampling were 
recruited through either of 2 mechanisms: contact with 
MMP staff or contact with a health care provider. The 
strategy used was dependent upon clinic needs, project 
area needs, and patient load. For recruitment by MMP 
staff, facilities provided local MMP staff with contact 
information for patients. For recruitment by a health 
care provider, patients selected to participate were ini-
tially contacted by their health care provider (or staff) 
in person, by telephone, or by mail. MMP project area 
staff would then contact the patient directly to arrange 
an interview. 
MMP DATA COLLECTION
Persons who agreed to participate were interviewed in 
a private location—at home, in a clinic, or at another 
mutually agreed upon location. Interviewers obtained 
informed consent and conducted face-to-face inter-
views. Each interview lasted approximately 45 min-
utes and consisted of questions concerning 
participants’ demographic characteristics, access to 
health care, usual source of care, adherence to ARV 
medications, preventive therapy, reproductive or 
gynecologic history (women only), vaccinations, 
unmet needs, (service utilization), sexual behavior, 
and drug and alcohol use. Two optional modules—
health and well-being (not presented) and assessment 
of prevention activities—were used in 2005. A total of 
9 areas (Delaware, Houston [Texas], Los Angeles 
County [California], Maryland, Michigan, New Jer-
sey, Philadelphia [Pennsylvania], South Carolina, and 
Texas) implemented the optional prevention module 
in the 2005 pilot. Participants received $25 in cash or 
a gift card in exchange for their time in taking part in 
the interview. 
This report presents results based on interview data 
from the pilot cycle of MMP in the 10 participating 
project areas that conducted interviews. From May 
2005 through December 2005, a sample of 2,390 per-
sons was selected from 107 facilities.
A total of 900 interviews were conducted during 
January 2006–August 2007. For the purposes of this 
report, interview data were excluded for one partici-HIV Special Surveillance Report 6pant for whom gender was missing. This report pres-
ents the results of a descriptive analysis (no statistical 
tests were performed) of data from 899 interviews.
The data presented in this report are subject to sev-
eral limitations and should be interpreted with caution. 
First, because these data are from the pilot cycle of 
MMP in an initially funded subset of sampled areas 
and not all sampled patients were contacted or inter-
viewed, the findings are neither nationally nor locally 
representative (i.e., they cannot be generalized to all 
U.S. states, territories, and cities). Second, the survey 
was administered via in-person interview, so some 
responses may be inaccurate: that is, participants may 
have underreported a socially undesirable behavior 
(e.g., drug use) and overreported a socially desirable 
behavior (e.g., adherence to ARV medication). Third, 
stratification by some characteristics may have pro-
duced numbers that are too small for reliable interpre-
tation. Further analyses of MMP data from future 
cycles, which will include larger numbers of project 
areas and participants, are planned.9
Table 1. Participants, by selected characteristics—Medical Monitoring Project, 2005  
Characteristic No. %
Project area
Philadelphia, PA 207 23
Delaware 184 20
Los Angeles County, CA 138 15
Washington 132 15
Texas 86 10
Houston, TX 46 5
Maryland 41 5
South Carolina 27 3
Michigan 26 3










Hispanic or Latino 143 16
American Indian or Alaska Native 6 1
Multiracial 21 2
Otherc 38 2







<High school 248 27
High school diploma or equivalent 286 32
>High school 362 40
Country or territory of birth
United States 781 87
Mexico 52 6
Puerto Rico 10 1
Other 56 6
Years since HIV diagnosis
5 581 65
<5 186 21
Homelessd at any time in the past 12 months
Yes 66 7
No 833 93
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Table 1. Participants, by selected characteristics—Medical Monitoring Project, 2005 (cont)
Characteristic No. %
Health insurance or coverage, past 12 months
Yes 768 85
No 130 14




Source of payments for HIV-related prescriptions, past 12 monthsf
Health care coverage 607 67
ADAP 195 22
Not taking any prescription medicines for HIV or related illnesses 40 4
Paid for HIV medicines themselves (“out of pocket”) 33 4
Got HIV medicines at a public clinic 26 3
Medicines provided by an AIDS service organization 7 <1
Source of most income or financial support, past 12 months
SSI or SSDI 449 50
Salary or wages 304 34
Public assistance 46 5
Spouse, partner, or family 39 4
No income or financial support 13 1
Pension/retirement fund 12 1
Friends 5 <1
Savings/investments 5 <1
Applied for public assistance, past 12 months
Yes 190 21
No 708 79
Received public assistance, past 12 months
Yes 582 65
No 316 35
Note. N = 899. Numbers may not add to total because of missing data. Values exclude cell sizes of <5, don't-know responses, and refusals to answer.
HMO, health maintenance organization; ADAP, AIDS Drug Assistance Program; SSI, Supplemental Security Income; SSDI, Social Security Disability 
Insurance.
a Participants were classified as transgender if gender at birth and sexual identity were discordant or if the participant chose “transgender” in response 
to the gender question. 
b Hispanics or Latinos may be of any race.
c Includes Asian and Native Hawaiian/Pacific Islander: numbers are too small to be presented separately. 
d Living on the street, in a shelter, a single-room-occupancy hotel, temporarily staying with friends, or living in a car. 
e Participants could select more than one response. This question was asked of 768 participants who reported health insurance or coverage during the 
past 12 months (i.e., denominator was 768).
f Participants could select more than one response.
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Table 2. Reasons for delaying HIV care entry 4 months—Medical Monitoring Project, 2005  
Reasona
Delayed care entry 4 months
No. %
Didn’t want to think about being HIV-positive 49 37
Didn’t want to believe HIV test result 28 21
Felt good, didn’t need to go 18 14
Drinking or using drugs 8 6
Didn’t know where to go 5 4
Note. N = 132 participants who reported receiving care 4 months after HIV diagnosis (defined as delayed care) and who reported dates of HIV 
diagnosis and entry into care; 612 participants reported receiving care within 4 months after diagnosis, and 155 participants had missing or invalid 
values for dates of HIV diagnosis, entry into care, or both.
a Participants could select more than one response.
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Table 3. Met and unmet needs for ancillary services during the past 12 months—Medical 
Monitoring Project, 2005 
Service
Needed service Unmet needb for service
No. %a No. %c
HIV case management 414 46 36 9
Mental health counseling 269 30 31 12
Social services (e.g., insurance assistance or financial counseling) 267 30 31 12
Assistance finding dental services 249 28 51 20
Transportation assistance 205 23 30 15
Assistance finding meals or food 178 20 15 8
Education or information about HIV risk reduction 159 18 12 8
Assistance finding shelter or housing 146 16 52 36
Assistance finding a doctor for ongoing care 122 14 9 7
Adherence support 93 10 9 10
Home health (e.g., home nursing care or assistance) 76 9 11 14
Chore or homemaker 60 7 15 25
Child care 18 2 2 11
Other 32 4 16 50
Note. N = 892 participants who were asked about needs.
a Percentage of participants who said they had needed the service during the past 12 months (denominator = 892).
b Defined as a need that the participant experienced during the past 12 months but that the participant was unable to obtain during that period.
c Denominator = the number of participants who needed the specific service (e.g., for HIV case management, the denominator = 414).HIV Special Surveillance Report 6 13
Figure 1. Most recent self-reported CD4+ T-lymphocyte count during the past 12 months—
Medical Monitoring Project, 2005
Most recent CD4+ T-lymphocyte count (cells/mm3)
Note. N = 690 participants who knew the result of their most recent CD4+ T-lymphocyte test.
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Figure 2. Self-reported number of CD4+ T-lymphocyte tests during the past 12 months—
Medical Monitoring Project, 2005
Number of CD4+ T-lymphocyte tests
Note. N = 834 participants who had at least one CD4+ T-lymphocyte test.
HIV Special Surveillance Report 6 15
Figure 3. Most recent self-reported HIV viral load result during the past 12 months—
Medical Monitoring Project, 2005
Most recent HIV viral load result (copies/ml)
Note. N = 646 participants who knew the result of their most recent HIV viral load test.
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Figure 4. Self-reported number of HIV viral load tests during the past 12 months—Medical 
Monitoring Project, 2005
Number of HIV viral load tests
Note. N = 818 participants who had at least one HIV viral load test.
HIV Special Surveillance Report 6 17
Table 4. Most common reasons for not currently taking antiretroviral medications—Medical 
Monitoring Project, 2005  
Reasona No. %
Doctor advised to delay treatment 25 31
Worried about side effects 18 23
CD4 count or viral load or both are good 16 20
Feel good, so don’t need them 13 16
Note. N = 80 participants who were not currently taking antiretroviral medications.
a Participants could report more than one reason.
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Table 5. Most common reasons for not taking most recent antiretroviral dose—Medical 
Monitoring Project, 2005 
Reasona No. %b
Forgot to take them 89 37
Had a change in daily routine 40 17
Was busy with other things 27 11
Wanted to avoid side effects 20 8
Felt depressed or overwhelmed 11 5
Had problems taking pills at specified times (e.g., with meals, on an empty stomach) 6 3
Note. N = 239 participants who were currently taking antiretroviral medications and who reported at least one reason for not taking their most recent
ARV dose.
a Participants could report more than one reason.
b Percentage of participants who had missed a dose during the past month.HIV Special Surveillance Report 6 19
Table 6. Noninjection drug use during the past 12 months, by type of drug—Medical Monitoring 
Project, 2005  
Type of drug No. %
Marijuana 200 72
Cocaine (smoked or snorted) 68 24
Crack 68 24
Methamphetamines 48 17
Poppers (amyl nitrate) 43 16
Painkillers (e.g., Oxycontin, Vicodin, Percocet) 30 11
Downers (e.g., Valium, Ativan, Xanax) 29 10
X, or Ecstasy 12 4
Heroin or opium (smoked or snorted) 11 4
GHB 9 3
Special k (ketamine) 6 2
Hallucinogens 5 2
Note. N = 277. Drugs used by <5 persons are not reported in this list.
GHB, gamma hydroxybutyrate. 
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Table 7. Injection drug use during the past 12 months, by type of drug—Medical Monitoring 
Project, 2005  




Heroin and cocaine 10 32
Crack 6 19
Note. N = 31. Drugs used by <5 persons are not reported in this list.
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Figure 5. Unprotected anal and/or vaginal sex with at least one partner during the past 12 
months, by gender of patient and sex partner—Medical Monitoring Project, 2005
Note. N = 496. The following categories are not mutually exclusive: “men who have sex with men” and “men who have sex with women.” Data for 
transgender respondents not reported because of small numbers.
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Figure 6. Knowledge of HIV status of most recent sex partner during the past 12 months, by 
gender of patient and sex partner—Medical Monitoring Project, 2005
Note. N = 483. The following categories are not mutually exclusive: “men who have sex with men” and “men who have sex with women.” Data for 
transgender respondents not reported because of small numbers. 
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